CannabisNewsBreaks

MondayJan 23, 2023 1:30 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a new strategic advisor. The company announced that Julian Gangolli, the former president of GW Pharmaceuticals USA, has joined Lexaria as a strategic advisor. During his time at GW Pharmaceuticals, Gangolli managed US Food and Drug Administration approval of Epidiolex(R), the only pure cannabidiol (“CBD”) drug ever approved by the agency; he also oversaw the commercialization of the drug in the United States, which ultimately led to Jazz Pharmaceuticals acquiring GW Pharmaceuticals in a $7.2 billion transaction. In addition to his work at GW Pharmaceuticals, Gangolli served as North…

Continue Reading

TuesdayJan 17, 2023 2:16 pm

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Positioned in Rapidly Growing Vertical Farming Space

Advanced Container Technologies (OTC: ACTX) today released a forecast on the expected bright future of the controlled environment agriculture sector, which includes vertical farming and the company’s own unique, portable indoor farms called GrowPods. According to the update, Morning Brew reports that vertical farming is “growing like a weed,” while BIS Research projects the sector could expand at a CAGR of 24.30% to become a nearly $20 billion market worldwide by 2029. Doug Heldoorn, CEO of ACTX, describes GrowPods as solutions set to take advantage of this trend. Transportable and scalable, they can provide fresh, nutritious food on a consistent…

Continue Reading

TuesdayJan 17, 2023 11:15 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter

Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka has released an annual letter to shareholders. The detailed letter talks about company highlights throughout the year, including the fact that, despite challenges such as global supply chain disruptions and threatening inflation, “Lexaria continues to navigate well and is focused on those things it can control such as applied R&D designed to entice others to work with us commercially. . . . [The company] has not terminated any staff and in fact our in-house team as well as our external consultant head-count has never been higher, in order to conduct and [analyze] an…

Continue Reading

FridayJan 13, 2023 3:45 pm

CannabisNewsBreaks – REZYFi Inc. Positioning to Operate Competitively in Challenging Lending Markets

REZYFi, a specialized financing company and a growing mortgage lender, is working to help businesses navigate the challenging landscape of loan origination, particularly as it applies to the traditionally underserved cannabis industry and property owners who lease to such companies. “REZYFi is anticipating the launch of its high-margin cannabis division in the coming weeks to focus on such challenging lending markets. The company is developing a proprietary technology that will help it operate competitively by maintaining efficient turnaround time while also being economical with staffing levels,” a recent article reads. “Through its subsidiaries, REZYFi Lending and ResMac Inc., the company…

Continue Reading

FridayJan 13, 2023 11:34 am

CannabisNewsBreaks – IBN Expands Collaboration with NECANN for 2023 Event Series

IBN, a multifaceted financial news and publishing company, today announced expansion of its multi-year collaboration with NECANN to serve as an official newswire for its upcoming conferences in 2023. NECANN organizes events around the establishment and growth of cannabis markets and associated opportunities in carefully selected communities with the potential to usher in the normalization of consumption and supportive policy frameworks. Under the collaboration, IBN will provide additional outreach via its syndication network for NECANN events, leveraging an extensive array of corporate-communications solutions to heighten visibility and drive recognition of conference participants among various audiences. “NECANN events are unique for…

Continue Reading

ThursdayJan 12, 2023 2:32 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

Continue Reading

TuesdayJan 10, 2023 11:38 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed…

Continue Reading

MondayJan 09, 2023 1:13 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline…

Continue Reading

ThursdayJan 05, 2023 11:24 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Releases Status Update on Commercial Cannabis Export Business

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is reporting on its commercial cannabis operations out of Colombia. According to the status update, the company exported an estimated 1,000 kilograms of commercial cannabis dry flower and derivatives to Europe and the United States in the fourth quarter of 2022; the company also received an updated cannabis export and production quota from the Colombian government, which included the addition of four additional proprietary genetics and increased production for domestic medical markets. The company noted that this activity is a result of the full…

Continue Reading

WednesdayJan 04, 2023 10:53 am

CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with phase 2 trials in Canada. “We are pleased to have received this no objection letter from Health Canada, which allows us to begin phase 2 trials on our drug formulation IGC-AD1 at sites throughout Canada,” said Ram Mukunda, CEO…

Continue Reading